<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName A++V2.4.dtd?>
  <?SourceDTD.Version 2.4?>
  <?ConverterInfo.XSLTName springer2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Curr Colorectal Cancer Rep</journal-id>
      <journal-title-group>
        <journal-title>Current Colorectal Cancer Reports</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1556-3790</issn>
      <issn pub-type="epub">1556-3804</issn>
      <publisher>
        <publisher-name>Current Science Inc.</publisher-name>
        <publisher-loc>New York</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3029665</article-id>
      <article-id pub-id-type="pmid">21423316</article-id>
      <article-id pub-id-type="publisher-id">84</article-id>
      <article-id pub-id-type="doi">10.1007/s11888-010-0084-8</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fecal Tests: From Blood to Molecular Markers</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Young</surname>
            <given-names>Graeme P.</given-names>
          </name>
          <address>
            <email>graeme.young@flinders.edu.au</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bosch</surname>
            <given-names>Linda J. W.</given-names>
          </name>
          <address>
            <email>ljw.bosch@vumc.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Flinders Centre for Cancer Prevention and Control, Department of Gastroenterology and Hepatology, Flinders Medical Centre, Flinders University, Bedford Park, Adelaide, 5042 Australia </aff>
        <aff id="Aff2"><label>2</label>Department of Pathology, VU University Medical Center, PO Box&#xA0;7057, 1007 MB Amsterdam, The Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2011</year>
      </pub-date>
      <volume>7</volume>
      <issue>1</issue>
      <fpage>62</fpage>
      <lpage>70</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2011</copyright-statement>
      </permissions>
      <abstract>
        <p>Detection of molecular markers for colorectal neoplasia in feces has the potential to improve performance of simple noninvasive screening tests for colorectal cancer. Most research has explored the value of DNA-based, RNA-based, and protein-based markers. In all cases there has been a trend to move from a single marker to a panel of markers to improve sensitivity. Unfortunately, no type of molecular marker has proved specific for neoplasia. DNA tests have been improved by combining mutation detection with assessment of DNA integrity plus epigenetic markers of neoplasia. RNA-based approaches are just beginning to explore the full power of transcriptomics. So far, no protein-based fecal test has proved better than fecal immunochemical tests for hemoglobin. Finally, no marker or panel of markers has yet been developed to the point where it has been evaluated in large unbiased population studies to assess performance across all stages of neoplasia and in all practical environments.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Screening</kwd>
        <kwd>Colorectal cancer</kwd>
        <kwd>Screening tests</kwd>
        <kwd>Molecular tests</kwd>
        <kwd>Genomics</kwd>
        <kwd>Transcriptomics</kwd>
        <kwd>Proteomics</kwd>
        <kwd>Biomarkers</kwd>
        <kwd>Sensitivity</kwd>
        <kwd>Specificity</kwd>
        <kwd>Neoplasia</kwd>
        <kwd>Oncogenesis</kwd>
        <kwd>Adenomas</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media, LLC 2011</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Progressive genomic instability in the colorectum gives rise to colorectal cancer (CRC) due to the accumulation of genetic alterations (gene mutations, gene amplification, etc.) and epigenetic alterations (aberrant DNA methylation, chromatin modifications, etc.) that transform epithelial cells into carcinoma cells. Altered function of proto-oncogenes and tumor suppressor genes results in disturbances of biological processes such as DNA repair, proliferation, and apoptosis. Several different molecular pathways of oncogenesis have been defined [<xref ref-type="bibr" rid="CR1">1</xref>&#x2022;, <xref ref-type="bibr" rid="CR2">2</xref>]. Our understanding of the underlying and associated molecular changes is increasing; specific changes at the DNA, RNA, and protein levels are being discovered as well as metabolic and other changes. These &#x201C;molecular&#x201D; changes have the potential to serve as biomarkers for neoplasia and may be useful for screening, diagnosis, prognostication, predicting responses to therapy, and detecting recurrence provided that they can be measured in biological materials such as blood or feces.</p>
      <p>This review aims to provide an update on the concepts underlying the use of molecular biomarkers for screening, how new biomarkers can be evaluated, and which show promise for use in screening. We will not consider tests for fecal blood in this review, even though some specifically target the hemoglobin molecule (ie, fecal immunochemical tests, FIT [<xref ref-type="bibr" rid="CR3">3</xref>&#x2022;]) nor will we consider blood-based molecular tests which are fast becoming an increasingly active area of research.</p>
    </sec>
    <sec id="Sec2">
      <title>Proven Simple Screening Tests</title>
      <p>Multiple population-based randomized trials have proved that guaiac-based fecal occult blood tests (GFOBT) detect early-stage disease and result in a reduced mortality from and incidence of CRC [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. In other words, early detection of lesions with a &#x201C;bleeding phenotype&#x201D; is beneficial in that one can be confident that treatment (surgery, polypectomy, etc.) will result in worthwhile gains.</p>
      <p>A single targeted population-based randomized trial has proved that flexible sigmoidoscopy detects early-stage disease and results in a reduced mortality from and incidence of CRC [<xref ref-type="bibr" rid="CR6">6</xref>&#x2022;&#x2022;]. Detection by endoscopic methods requires only that a lesion be visualizable and since such is independent of the bleeding phenotype, this trial indicates that treatment benefit for early neoplastic lesions is probably independent of tumor phenotype or genotype. This is a crucial point because expression of a molecular biomarker by a tumor might reflect a certain biological behavior that reflects natural history or is related to or determines response to therapy. For example, a lesion might grow so slowly as to not even need treatment within a lifetime or, conversely, it might be so aggressive as to render curative treatment pointless.</p>
    </sec>
    <sec id="Sec3">
      <title>Evaluating New Screening Biomarkers</title>
      <p>There are relatively few practical guidelines on how best to compare &#x201C;new&#x201D; with proven screening tests and it is not the purpose of this review to critique these strategies but it is clear that new tests cannot be initially subject to randomized controlled trials (RCTs) with mortality or incidence as the end point. Strategically, it is expedient to evaluate a biomarker&#x2019;s diagnostic performance relative to a proven comparator screening test in highly selected cases with cancer [<xref ref-type="bibr" rid="CR7">7</xref>]. But evaluation of test accuracy must be backed up by programmatic evaluation in the screening context where prevalence is low and non-neoplastic lesions are present [<xref ref-type="bibr" rid="CR8">8</xref>] such that we know how the test performs across the spectrum of prevalent neoplastic lesions. Such is essential for a new test to be adopted for widespread use.</p>
      <p>A phased evaluation of a new biomarker is recommended [<xref ref-type="bibr" rid="CR8">8</xref>]. Initial evaluation of biomarkers will usually be undertaken in small numbers of highly selected cases, often retrospective (such as those with symptomatic cancer versus normal controls) and using colonoscopy as the reference standard [<xref ref-type="bibr" rid="CR9">9</xref>]. If promising, evaluation should proceed to comparison with a proven screening test such as an FOBT (ideally a FIT [<xref ref-type="bibr" rid="CR3">3</xref>&#x2022;]) but such need not include cancer-specific mortality as an end point provided that the comparator test&#x2019;s effect on population mortality has been proven by a population randomized controlled trial [<xref ref-type="bibr" rid="CR7">7</xref>]. Guaiac-FOBT effectiveness represents the <italic>minimum</italic> standard to be achieved by a new test since GFOBT are effective (albeit limited) and inexpensive. Finally, a prospective evaluation of performance across the continuum of neoplastic lesions from adenoma to cancer should be undertaken in large unselected typical screening populations.</p>
      <p>Such comparative studies focus initially on relative detection, but screening is about more than detection; it is about success when applied to many healthy people where disease prevalence is low and acceptability of the test is crucial. Demonstration of adequate accuracy in prescreening phases justifies progression to mass-population studies that address programmatic outcomes on an intention-to-screen basis followed by evaluation of cost-effectiveness in ongoing screening.</p>
      <p>It will be apparent from the following discussions that fecal molecular tests have not yet progressed to evaluation by randomized fashion in large unselected populations.</p>
    </sec>
    <sec id="Sec4">
      <title>How Might Molecular Markers Improve Screening Outcomes?</title>
      <p>Screening by existing proven methods has disadvantages one way or another. Endoscopic methods are invasive and inconvenient and when used as the primary screening tool are used on many people who will prove to have no neoplastic lesions in the colon. FOBT methods, while simple and increasing the likelihood of neoplasia being present when positive, are not specific for neoplasia, and have somewhat limited sensitivity for cancer and especially adenomas [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], although FIT are a major improvement over GFOBT [<xref ref-type="bibr" rid="CR3">3</xref>&#x2022;].</p>
      <p>It would be useful to have simple and acceptable noninvasive screening tests that are more specific for neoplasia, ie, have a lower false-positive rate. If so, this will reduce costs of diagnostic follow-up, workloads, and overall program cost.</p>
      <p>It would also be valuable if simple and acceptable noninvasive screening tests were more sensitive for curable cancer and more advanced adenomas, ie, return a higher true-positive rate. This would improve impact on mortality and incidence.</p>
      <p>While it is known that limitations of existing simple tests, namely FOBT, include lack of specificity for neoplasia and variation between tumors as to whether they bleed or not [<xref ref-type="bibr" rid="CR11">11</xref>], it needs to be shown, if simple molecular tests are to replace FOBT, that they do indeed point to molecular phenomena that are either more predictable than bleeding and/or more characteristic of neoplasia.</p>
      <p>Finally, sensitivity and specificity are both important and improving one at the expense of the other does not necessarily provide an advantage.</p>
    </sec>
    <sec id="Sec5">
      <title>Detection of Neoplasia Using Biomarkers</title>
      <p>Colorectal oncogenesis follows several genetic pathways [<xref ref-type="bibr" rid="CR1">1</xref>&#x2022;, <xref ref-type="bibr" rid="CR2">2</xref>]. The process is protracted and takes years, perhaps decades, from the initial event that initiates oncogenesis until sufficient molecular events accumulate to change cell behavior and result in the invasive phenotype (ie, cancer) [<xref ref-type="bibr" rid="CR1">1</xref>&#x2022;, <xref ref-type="bibr" rid="CR12">12</xref>]. This sequence underlies the phenotypic progression known as the adenoma-carcinoma sequence. The stage of neoplasia at which a biomarker becomes expressed and detectable (ie, &#x201C;positive&#x201D;) is crucial to what we hope molecular biomarkers will detect in the screening context. A positive biomarker initiates diagnostic confirmation by colonoscopy.</p>
      <p>Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref> provides a conceptual presentation of the most advanced stage of colorectal neoplasia reached by the time of death (&#x201C;life-time state&#x201D;) for a typical Western population [<xref ref-type="bibr" rid="CR11">11</xref>&#x2022;&#x2022;]. Curable neoplastic lesions are the obvious target. Curable cancer (point C in the process in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) is a key target, as the GFOBT RCTs showed that detection of curable cancer (ie, downstaging of cancer) leads to reduction in mortality [<xref ref-type="bibr" rid="CR4">4</xref>]. Detection and removal of adenomas (particularly advanced adenomas, point B in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) is also a worthwhile target as the flexible sigmoidoscopy RCT showed a reduction in incidence as did one GFOBT RCT [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>&#x2022;&#x2022;]. These studies support the recent US multi-society guidelines that recommended that screening target not just early-stage cancer but also &#x201C;advanced&#x201D; adenomas [<xref ref-type="bibr" rid="CR13">13</xref>&#x2022;&#x2022;]. Advanced adenomas are defined as those of &gt;9&#xA0;mm, those with villous change, or those showing high-grade dysplasia [<xref ref-type="bibr" rid="CR14">14</xref>].
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Conceptual presentation of the approximate proportion of a typical Western population and the most advanced stage of colorectal neoplasia reached by the time of death (life-time &#x201C;state&#x201D;). Points A&#x2013;D refer to examples of states at which a biomarker might provide information (see text for discussion)</p></caption><graphic xlink:href="11888_2010_84_Fig1_HTML" id="MO1"/></fig></p>
      <p>It can be seen that different biomarkers might characterize different stages of oncogenesis and so vary in their usefulness.</p>
      <p>Small, tubular, low-grade adenomas (point A in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) are more common than large, high-grade, or villous lesions. Detection of early, small adenomas might not be useful in that they pose little risk for CRC [<xref ref-type="bibr" rid="CR15">15</xref>]&#x2014;detection of inconsequential neoplastic lesions is referred to as over-diagnosis and is a major issue for prostate cancer screening [<xref ref-type="bibr" rid="CR16">16</xref>]. Detection of incurable neoplasia (biomarker point D in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>), likewise, would not lead to benefit.</p>
      <p>In other words, there is a gradation of probability of progression from adenoma to cancer, with the more advanced lesions more likely to progress to cancer; biomarkers for adenomas will vary in their capacity to predict likelihood of progression to cancer according to the stage detected, as not all small adenomas progress to advanced adenomas [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], and test sensitivity.</p>
      <p>It also needs to be noted that with the different molecular pathways of oncogenesis, some molecular markers might be pathway specific. So, to reliably detect neoplasms, a panel of molecular markers might be needed.</p>
    </sec>
    <sec id="Sec6">
      <title>Biomarkers in Feces</title>
      <p>Apart from these biological considerations with regard to different stages of and pathways to cancer, we also need to consider the way in which a biomarker gets into the biological sample in which we want to measure it such as feces, and whether it remains detectable. This is important because most biomarkers are first &#x201C;discovered&#x201D; in neoplastic tissues but will be sought in biological samples where their chemical nature may be different.</p>
      <p>Feces is comprised of water, undigested food, bacterial biomass, shed cells, fragments of cells, and other products from cells and vessels (blood and lymphatics). A clinically useful test for a biomarker must be able to detect a molecule in this complex and highly destructive mix that contains many enzymes and other substances that will change the characteristics of a marker, often by degradation.</p>
      <p>The evidence indicates that neoplasms are associated with &#x201C;leakage&#x201D; of cellular and vascular materials as well as shedding of cells into feces. Colonocytes are continuously shed into the fecal stream [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;]. Markers can be classified as those that leak through neoplasms, are secreted by neoplasms, or arise by exfoliation [<xref ref-type="bibr" rid="CR20">20</xref>]. To these we should add shedding of cell fragments by events such as apoptosis and release of tiny membranous vesicles (termed exosomes) [<xref ref-type="bibr" rid="CR21">21</xref>]. Biomarkers might arise from the neoplasm itself, reflect a cellular response to the neoplasm, or simply result from its physical presence (eg, leakage of plasma proteins). Whatever the case, the biomarker needs to be stable to ensure reliable detection. This might require a sample such as feces to be collected under stringent conditions so as to ensure its usefulness. This has proved to be crucial even for DNA, which is known to be more stable than protein or RNA in biological samples. A device appropriate for ensuring that fecal DNA is of adequate quality has been developed [<xref ref-type="bibr" rid="CR22">22</xref>], but this is costly and logistically involved.</p>
      <p>Ultimately, stability of a biomarker in feces and simplicity of collection of a stable sample will be crucial determinants of the practical usefulness of a biomarker.</p>
    </sec>
    <sec id="Sec7">
      <title>Molecular Markers in Feces</title>
      <p>As indicated above, it is known that biomarkers may gain access to feces by many routes. It is also known that neoplastic cells are less subject to apoptotic breakdown and represent a proportionally higher fraction of fecal epithelial cells when neoplasia is present [<xref ref-type="bibr" rid="CR23">23</xref>]. Potential markers could fall anywhere along the &#x201C;omics&#x201D; flow of information processing relating to cell phenotype and behavior:
<list list-type="bullet"><list-item><p>Genomics: DNA, reflecting genetic (eg, mutations) and epigenetic changes (eg, aberrant methylation) that are characteristic of colorectal oncogenesis</p></list-item><list-item><p>Transcriptomics: mRNA and microRNA, reflecting expression patterns characteristic of neoplasia</p></list-item><list-item><p>Proteomics: Proteins, reflecting abnormalities dependent on translational or post-translational processing</p></list-item><list-item><p>Metabolomics: Other biochemical events characteristic of neoplasia.</p></list-item></list></p>
      <p>Biochemical methods such as mutation analysis, next-generation sequencing, microarrays, and proteomics may all provide an option for detecting markers.</p>
      <p>It is important to note that molecular markers in feces potentially arise from any region of the aerodigestive system. Ideally, one would use a marker that has selectivity for colorectal neoplasia. A marker not specific for a given organ-cancer raises the possibility of needing to pursue the possibility of cancer anywhere in the aerodigestive tract. This would be costly and of questionable benefit.</p>
    </sec>
    <sec id="Sec8">
      <title>Fecal DNA Markers</title>
      <sec id="Sec9">
        <title>DNA Markers in Feces: Pros and Cons</title>
        <p>In a recent review, it has been pointed out that most studies of stool-based DNA biomarkers have focused on the detection of aberrant DNA originating from cancers [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;]. Several biological mechanisms help to increase the potential to specifically detect tumor DNA in stool. Whereas DNA in normal cells is degraded upon shedding by rapid induction of apoptosis, shed tumor cells may escape from apoptosis with reduced loss of DNA integrity because apoptosis is reduced in neoplasms [<xref ref-type="bibr" rid="CR23">23</xref>]. Thus, a simple general measure of DNA integrity may be useful.</p>
        <p>Genetic markers may, alternatively, be very specific. But, many different point mutations characterize colorectal oncogenesis and while a given gene might be a common target for mutations, many different gene probes will be needed to detect all the relevant mutations. Furthermore, the mere presence of an oncogenic mutation in a cell does not guarantee progression to cancer [<xref ref-type="bibr" rid="CR1">1</xref>&#x2022;]. Consequently, mutation detection is biologically limited, perhaps more so than is detection of a bleeding phenotype using an FOBT.</p>
        <p>Next to genetic alterations such as mutations, epigenetic changes play an important role in deregulating gene expression in CRC [<xref ref-type="bibr" rid="CR2">2</xref>]. Hypermethylation of the promoter region of a gene, which can cause silencing of tumor suppressor genes in many cancers, is a well studied example. Many genes have been reported to be hypermethylated in colorectal cancer [<xref ref-type="bibr" rid="CR24">24</xref>], and these alterations appear to be early events in carcinogenesis [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;]. The latest developments in stool-based DNA tests take advantage of both genetic (precise and global) and epigenetic changes.</p>
      </sec>
      <sec id="Sec10">
        <title>DNA Biomarker Evaluation</title>
        <p>Bosch et al. [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;] provide a comprehensive and thorough review of stool-based DNA markers and the present review will focus on the key issues arising from the many studies undertaken. Bosch et al. found 19 papers looking at multiple biomarkers in stool and 18 evaluating &#x201C;single&#x201D; (or single class) gene markers [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;]. For single markers, mutations in <italic>K-ras</italic> and <italic>APC</italic> were initially studied and eventually discarded as being useful in themselves. Most studies were small, involved highly selected clinical (rather than screen-detected) cohorts, and cases with adenomas were generally not included; as a generalization, sensitivities for cancer ranged from around 40% to almost 90%.</p>
        <p>Investigators progressed to include methylation and other markers. A range of genes has been tested for methylation&#x2014;<italic>SFRP2, TFPI2, GATA4, NDRG4, OSMR</italic>, and vimentin&#x2014;with no one marker emerging as obviously the best [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;]. The DNA integrity assay for long-chain DNA (the DIA assay) [<xref ref-type="bibr" rid="CR23">23</xref>] has also been included [<xref ref-type="bibr" rid="CR25">25</xref>&#x2022;]. As a generalization, specificities ranged from 80% upwards for these markers, making it clear that such molecular tests did not guarantee specificity for neoplasia.</p>
        <p>In parallel, investigators have pursued the value of multiple markers, evaluated as a panel. Combinations of mutation analysis of several genes with and without markers of MSI (microsatellite instability), methylation, and or DIA have been evaluated, again mainly in highly selected clinical cohorts of patients with cancer. As a generalization, detection was somewhat improved and specificity tended to be in the range of 90% to 95% [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;].</p>
        <p>A large study promised much for DNA panels [<xref ref-type="bibr" rid="CR26">26</xref>]. The detection rate of cancer using a panel of markers based on key tumor suppressor and oncogenes plus the DIA assay and MSI, was 52% sensitive for cancer compared to 13% using Hemoccult II GFOBT (<italic>P</italic> = 0.003). The sensitivity of both the panel and the GFOBT for detecting cancer or advanced adenoma was poor, however: 18.2% for the DNA panel compared to 10.8% for Hemoccult II (<italic>P</italic> = .001). The performance of both tests in detecting advanced adenomas was similarly disappointing (15.1% vs 10.7%, respectively). In patients with negative colonoscopy, 5.6% tested positive on fecal DNA (94.4% specific), compared to 4.8% with Hemoccult II (95.2% specific). The study has been criticized because of the uncharacteristically low sensitivity for cancer of Hemoccult II.</p>
        <p>Clearly, even a comprehensive DNA panel is biologically limited. Furthermore, the specificity of fecal DNA was no better than that of Hemoccult II. This might seem surprising, but the adenoma-carcinoma sequence is propagated through an accumulation of genomic events. Each event of itself is not capable of driving the oncogenic pathway to the point of colonoscopically detectable neoplasia.</p>
        <p>A similarly large study was subsequently reported using some technological advances of the same panel [<xref ref-type="bibr" rid="CR27">27</xref>&#x2022;&#x2022;]. This time, the panel detected only 25% of cancers (less than did the GFOBT Hemoccult) and 17% of adenomas greater than 1&#xA0;cm, with a specificity of 96%.</p>
        <p>Inclusion of vimentin methylation improved detection. Ahlquist et al. [<xref ref-type="bibr" rid="CR27">27</xref>&#x2022;&#x2022;] adapted the panel to comprise vimentin together with mutation analysis of <italic>K-ras</italic> and <italic>APC</italic> genes and detected 58% of cancers. Itzkowitz et al. [<xref ref-type="bibr" rid="CR28">28</xref>&#x2022;] combined vimentin with DIA to achieve 86% sensitivity but specificity was inadequate: the two studies returned specificities of 84% and 73%, respectively.</p>
        <p>Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> summaries the larger DNA studies (more than 200 cases/controls) published since 2003.
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Summary of studies since 2003 that have tested DNA markers in stools and have included more than 200 cases/controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Biomarker</th><th>Method</th><th>Study population</th><th>Sensitivity</th><th>Specificity</th></tr></thead><tbody><tr><td colspan="6">Single markers</td></tr><tr><td rowspan="2">&#xA0;Chen et al. [<xref ref-type="bibr" rid="CR29">29</xref>], 2005</td><td><italic>Vimentin</italic></td><td>Methylation analysis</td><td>94 cancers</td><td>46%</td><td/></tr><tr><td/><td/><td>198 controls</td><td/><td>90%</td></tr><tr><td rowspan="2">Calistri et al. [<xref ref-type="bibr" rid="CR25">25</xref>&#x2022;], 2009</td><td>L-DNA</td><td>FL-DNA, cutoff 25&#xA0;ng</td><td>100 cancers</td><td>79%</td><td/></tr><tr><td/><td/><td>100 controls</td><td/><td>89%</td></tr><tr><td colspan="6">Multiple markers</td></tr><tr><td rowspan="3">Tagore et al. [<xref ref-type="bibr" rid="CR30">30</xref>], 2003</td><td><italic>KRAS/ TP53 / APC</italic></td><td>Mutation analysis</td><td>52 cancers</td><td>64%</td><td/></tr><tr><td>MSI</td><td>MSI in BAT26</td><td>28 advanced adenomas</td><td>57%</td><td/></tr><tr><td>DIA</td><td>Presence of long DNA (four-site DIA)</td><td>212 controls</td><td/><td>96%</td></tr><tr><td rowspan="4">Imperiale et al. [<xref ref-type="bibr" rid="CR26">26</xref>], 2004</td><td><italic>KRAS / TP53 / APC</italic></td><td>Mutation analysis</td><td>31 cancers</td><td>52%</td><td/></tr><tr><td>MSI</td><td>MSI in BAT26</td><td>403 advanced adenomas</td><td>15%</td><td/></tr><tr><td>DIA</td><td>Presence of long DNA (four-site DIA)</td><td>648 polyps</td><td>8%</td><td/></tr><tr><td/><td/><td>1423 controls</td><td/><td>95%</td></tr><tr><td rowspan="4">Ahlquist et al. [<xref ref-type="bibr" rid="CR27">27</xref>&#x2022;&#x2022;], 2008</td><td><italic>KRAS / TP53 / APC</italic></td><td>Mutation analysis</td><td>12 cancers</td><td>25%</td><td/></tr><tr><td>MSI</td><td>MSI in BAT26</td><td>135 adenomas &gt;1&#xA0;cm</td><td>17%</td><td/></tr><tr><td>DIA</td><td>Long DNA (four-site DIA)</td><td>469 adenomas &lt;1&#xA0;cm</td><td>4%</td><td/></tr><tr><td/><td/><td>1473 controls</td><td/><td>96%</td></tr><tr><td rowspan="3">Ahlquist et al. [<xref ref-type="bibr" rid="CR27">27</xref>&#x2022;&#x2022;], 2008</td><td><italic>KRAS / APC</italic></td><td>Mutation analysis</td><td>19 cancers</td><td>58%</td><td/></tr><tr><td><italic>Vimentin</italic></td><td>Methylation analysis</td><td>103 adenomas &gt;1&#xA0;cm</td><td>46%</td><td/></tr><tr><td/><td/><td>75 controls</td><td/><td>84%</td></tr><tr><td rowspan="2">Itzkowitz et al. [<xref ref-type="bibr" rid="CR28">28</xref>&#x2022;], 2008</td><td><italic>Vimentin</italic></td><td>Methylation analysis</td><td>42 cancers</td><td>86%</td><td/></tr><tr><td>DIA</td><td>Long DNA (two-site DIA)</td><td>241 controls</td><td/><td>73%</td></tr></tbody></table><table-wrap-foot><p>Data extracted from Bosch et al. [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;]</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec11">
        <title>Conclusions</title>
        <p>DNA tests have great potential but as yet the ideal panel is far from clear. The technology continues to evolve. Thorough evaluation of such markers relative to different molecular pathways of oncogenesis remains to be undertaken. Costs of molecular tests remain high relative to FOBT although with advances in technology this seems likely to change. Unbiased mass population-based studies have not yet been undertaken.</p>
      </sec>
    </sec>
    <sec id="Sec12">
      <title>Fecal RNA Markers</title>
      <sec id="Sec13">
        <title>RNA Markers in Feces: Pros and Cons</title>
        <p>Tumor-derived RNA seems likely to get into stool by the same processes as DNA. In addition, RNA might gain access if cells secrete tiny membranous vesicles (termed exosomes) that carry RNA species from the cell of origin [<xref ref-type="bibr" rid="CR21">21</xref>]. Various types of RNA, not just mRNA (which code for proteins) but also microRNA (which are noncoding but greatly influence gene expression), will gain access to feces by these mechanisms. MicroRNAs have potential to be biomarkers for cancers [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
        <p>We know less about the value of RNA markers. A common approach has been to &#x201C;discover&#x201D; potential RNA-based markers by examining gene expression profiles, called transcriptomics, in neoplastic compared to normal tissue and then pursuing those markers that appear to differentiate neoplasia from non-neoplasia [<xref ref-type="bibr" rid="CR8">8</xref>]. Underlying this is the concept that gene expression patterns are unique for neoplasia (and ideally for neoplasia within a given organ) and that the differences between neoplasia and non-neoplasia are greater than variations within non-neoplasia (eg, along the length of the colon [<xref ref-type="bibr" rid="CR32">32</xref>&#x2022;] or variations related to diet). Measuring patterns of expression of large numbers of mRNA markers is becoming commonplace in biological research, although initial studies have focused on a single marker or small panel when searching for fecal markers [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;].</p>
        <p>Unfortunately, RNA is less stable than DNA and assay in feces creates major methodological challenges for preservation of samples and RNA stability.</p>
      </sec>
      <sec id="Sec14">
        <title>RNA Biomarker Evaluation</title>
        <p>The potential for stool RNA markers to be informative has been reviewed by Bosch et al. [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;]. Studies have focused principally on a single or small panel of markers.</p>
        <p>To date the most studied mRNA marker in stool has been <italic>PTGS2 (Cox-2</italic>, prostaglandin-synthase 2), but all studies have been restricted to highly selected cases with cancer. Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref> shows that sensitivities have ranged from 50% to 90%, with specificities of 93% or higher [<xref ref-type="bibr" rid="CR33">33</xref>&#x2013;<xref ref-type="bibr" rid="CR36">36</xref>]. Much larger cohorts that include disease controls are required if we are to assess whether this biomarker realizes its potential for use in a typical screening population.
<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Stool biomarker studies incorporating the RNA marker for cyclooxygenase-2 (<italic>PTGS2</italic> [<italic>COX-2</italic>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Biomarker</th><th>Method</th><th>Study population</th><th>Sensitivity</th><th>Specificity</th></tr></thead><tbody><tr><td colspan="6">Single markers</td></tr><tr><td rowspan="2">&#xA0;Kanaoka et al. [<xref ref-type="bibr" rid="CR33">33</xref>], 2004</td><td><italic>PTGS2</italic> (<italic>COX-2</italic>)</td><td>Nested RT-PCR</td><td>29 cancers</td><td>90%</td><td/></tr><tr><td/><td/><td>22 controls</td><td/><td>100%</td></tr><tr><td rowspan="3">&#xA0;Leung et al. [<xref ref-type="bibr" rid="CR34">34</xref>], 2007</td><td><italic>PTGS2</italic> (<italic>COX-2</italic>)</td><td>RT-PCR</td><td>20 cancers</td><td>50%</td><td/></tr><tr><td/><td/><td>30 adenomas</td><td>4%</td><td>93%</td></tr><tr><td/><td/><td>30 controls</td><td/><td/></tr><tr><td colspan="6">Multiple markers</td></tr><tr><td rowspan="2">&#xA0;Koga et al. [<xref ref-type="bibr" rid="CR35">35</xref>], 2008</td><td><italic>MMP7</italic> / <italic>MYBL2</italic> / <italic>PTGS2</italic> (<italic>COX-2</italic>) / TP53</td><td>Quantitative RTPCR</td><td>166 cancers</td><td>58%</td><td/></tr><tr><td/><td/><td>134 controls</td><td/><td>88%</td></tr><tr><td rowspan="2">&#xA0;Takai et al. [<xref ref-type="bibr" rid="CR36">36</xref>], 2009</td><td><italic>PTGS2</italic> (<italic>COX-2</italic>) / <italic>MMP7</italic></td><td>Nested RT-PCR</td><td>62 cancers</td><td>90%</td><td/></tr><tr><td/><td/><td>29 controls</td><td/><td>100%</td></tr></tbody></table><table-wrap-foot><p>Data extracted from Bosch et al. [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;]</p></table-wrap-foot></table-wrap></p>
        <p>Using larger panels of markers, for example, oligonucleotide microarrays, cancer-specific gene expression profiles can be built and used to discriminate between cancer and non-cancer. Using this approach, one study revealed that a panel of nine oligonucleotide probes (<italic>PAP</italic>, <italic>REG1A</italic>, <italic>DPEP1</italic>, <italic>SEPP1</italic>, <italic>RPL27A</italic>, <italic>ATP1B1</italic>, <italic>EEF1A1</italic>, <italic>SFN</italic>, and <italic>RPS11</italic>) gave a sensitivity of 78% for CRC, with a specificity of 100% [<xref ref-type="bibr" rid="CR37">37</xref>]. However, they used fecal colonocytes as the specimen for assay and applicability to stools is unclear.</p>
      </sec>
      <sec id="Sec15">
        <title>Conclusions</title>
        <p>Technological developments will have a big influence on whether this approach based on RNA, whether mRNA or microRNA, bears fruit. A panel of biomarkers seems likely to be needed. For now, we are far from a feasible test for clinical practice.</p>
      </sec>
    </sec>
    <sec id="Sec16">
      <title>Fecal Protein Markers</title>
      <sec id="Sec17">
        <title>Protein Markers in Feces: Pros and Cons</title>
        <p>The detection of proteins in feces is relatively easy since the protein of interest is often readily detected in small sample volumes using inexpensive technologies. FIT are just one example where simple qualitative or quantitative methods for detection can be developed and provided at a low cost. If new markers are shown to be stable in stool, then simple test platforms such as membrane lateral flow immunochemical devices or quantitative latex-agglutination can be developed to provide simple tests for mass screening.</p>
        <p>While some proteins are quite stable in feces, many undergo degradation by proteolytic enzymes. Glycoproteins are particularly subject to attack by glycosidases. Mass spectrometry may well provide means for detecting degraded markers and so &#x201C;proteomics&#x201D; might well deliver useful biomarkers.</p>
      </sec>
      <sec id="Sec18">
        <title>Protein Biomarker Evaluation</title>
        <p>To date a moderately large number of markers have been studied. Fifteen studies have been reviewed in depth [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;]. Apart from immunochemical assays for human hemoglobin itself, none has established a novel marker yet, although most studies have been simple cohort studies with few disease controls.</p>
        <p>Markers range from proteins derived from blood or plasma (eg, hemoglobin, calprotectin, haptoglobin) to possibly tumor-derived markers such as M2-PK&#x2013;pyruvate kinase type M2, S100A12&#x2013;S100 calcium-binding protein A12, and TIMP-1&#x2013;TIMP metallopeptidase inhibitor 1 [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;].</p>
        <p>Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref> summarizes those papers that have included two markers of interest, M2-PK and S100A12, that seem derived from tumors. Tumor M2-PK appears to have considerable potential [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], with sensitivity for cancer in a selected cohort of 78% to 85% and for adenomas in general of 23% to 38%. Combining S100A12 with hemoglobin, haptoglobin, and TIMP-1 in a study of over 500 patients shows sensitivity for cancer around 85% with better than 95% specificity [<xref ref-type="bibr" rid="CR41">41</xref>].
<table-wrap id="Tab3"><label>Table&#xA0;3</label><caption><p>Studies of stool biomarkers testing for two proteins of interest, M2-PK (pyruvate kinase type M2) and S100A12 (S100 calcium-binding protein A12)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Biomarker</th><th>Method</th><th>Study population</th><th>Sensitivity</th><th>Specificity</th></tr></thead><tbody><tr><td colspan="6">Single markers</td></tr><tr><td rowspan="4">&#xA0;Mulder et al. [<xref ref-type="bibr" rid="CR38">38</xref>&#x2022;], 2007</td><td>Tumor M2-PK</td><td>Immunoassay, cutoff 4 U/mL</td><td>52 cancers</td><td>85%</td><td/></tr><tr><td/><td/><td>47 adenomas</td><td>28%</td><td/></tr><tr><td/><td/><td>19 IBD</td><td>79%</td><td/></tr><tr><td/><td/><td>63 controls</td><td/><td>90%</td></tr><tr><td rowspan="3">&#xA0;Shastri et al. [<xref ref-type="bibr" rid="CR39">39</xref>], 2008</td><td>Tumor M2-PK</td><td>Immunoassay, cutoff 4 U/mL</td><td>55 cancers</td><td>78%</td><td/></tr><tr><td/><td/><td>69 adenomas</td><td>38%</td><td/></tr><tr><td/><td/><td>516 controls</td><td/><td>74%</td></tr><tr><td rowspan="3">&#xA0;Haug et al. [<xref ref-type="bibr" rid="CR40">40</xref>], 2008</td><td>Tumor M2-PK</td><td>Immunoassay, cutoff 4 U/mL</td><td>106 advanced adenomas</td><td>22%</td><td/></tr><tr><td/><td/><td>216 adenomas</td><td>23%</td><td/></tr><tr><td/><td/><td>649 controls</td><td/><td>82%</td></tr><tr><td colspan="6">Multiple markers</td></tr><tr><td rowspan="3">&#xA0;Karl et al. [<xref ref-type="bibr" rid="CR41">41</xref>], 2008</td><td>S100A12 / hemoglobin-haptoglobin / TIMP-1</td><td>Immunoassay, cutoff not reported</td><td>186 cancers</td><td>82%&#x2013;88%</td><td/></tr><tr><td/><td/><td>113 advanced adenomas</td><td>12%&#x2013;20%</td><td/></tr><tr><td/><td/><td>252 controls</td><td/><td>95%&#x2013;98%</td></tr></tbody></table><table-wrap-foot><p>Data extracted from Bosch et al. [<xref ref-type="bibr" rid="CR19">19</xref>&#x2022;&#x2022;]</p></table-wrap-foot></table-wrap></p>
        <p>Markers arising from leakage of blood have shown some ability to discriminate neoplasia from non-neoplasia but these have not replaced FIT in practice. These include the proteins haptoglobin [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>] and calprotectin, although the latter is highly sensitive for inflammatory bowel disease [<xref ref-type="bibr" rid="CR44">44</xref>].</p>
      </sec>
      <sec id="Sec19">
        <title>Conclusions</title>
        <p>Some of these show promise, but as with other biomarkers, until they are compared to a proven screening test such as GFOBT and evaluated in large typical screening populations, the potential usefulness remains uncertain. Extensive evaluation in disease controls is also needed because markers evaluated so far are not necessarily tumor-specific markers.</p>
      </sec>
    </sec>
    <sec id="Sec20">
      <title>General Conclusions</title>
      <p>The search for molecular biomarkers useful for screening for colorectal cancer has not yet led to a simple test that can replace FOBT. While good sensitivity has been achieved for cancer, sensitivity for adenomas has not been adequately explored. Furthermore, molecular tests are not proving to be any more specific for neoplasia than are FOBT, especially as tests are configured to optimize sensitivity. DNA tests have been improved by combining mutation detection with assessment of DNA integrity plus epigenetic markers of neoplasia. RNA-based approaches are just beginning to explore the full power of transcriptomics. So far, no protein-based fecal test has proved better than fecal immunochemical tests for hemoglobin. It seems likely that a panel of markers will be required to ensure that the various molecular pathways of oncogenesis and the different patterns of gene expression are adequately covered.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Disclosure</title>
      <p>No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref-list id="BSec1">
        <title>Papers of particular interest, published recently, have been highlighted as: &#x2022; Of importance &#x2022;&#x2022; Of major importance</title>
        <ref id="CR1">
          <label>1.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Grady</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Carethers</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Genomic and epigenetic instability in colorectal cancer pathogenesis</article-title>
            <source>Gastroenterology</source>
            <year>2008</year>
            <volume>135</volume>
            <fpage>1079</fpage>
            <lpage>99</lpage>
            <pub-id pub-id-type="doi">10.1053/j.gastro.2008.07.076</pub-id>
            <pub-id pub-id-type="pmid">18773902</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR2">
          <label>2.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Weisenberger</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Siegmund</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Campan</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer</article-title>
            <source>Nat Genet</source>
            <year>2006</year>
            <volume>38</volume>
            <fpage>787</fpage>
            <lpage>93</lpage>
            <pub-id pub-id-type="doi">10.1038/ng1834</pub-id>
            <pub-id pub-id-type="pmid">16804544</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR3">
          <label>3.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Young</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Which fecal occult blood test is best to screen for colorectal cancer?</article-title>
            <source>Nature Clinical Practice Gastroenterology and Hepatology</source>
            <year>2009</year>
            <volume>6</volume>
            <fpage>140</fpage>
            <lpage>141</lpage>
            <pub-id pub-id-type="doi">10.1038/ncpgasthep1358</pub-id>
            <pub-id pub-id-type="pmid">19174764</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR4">
          <label>4.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Mandel</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Bond</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>TR</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Reducing mortality from colorectal cancer by screening for fecal occult blood Minnesota Colon Cancer Control Study</article-title>
            <source>N.Engl.J.Med.</source>
            <year>1993</year>
            <volume>328</volume>
            <fpage>1365</fpage>
            <lpage>1371</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJM199305133281901</pub-id>
            <pub-id pub-id-type="pmid">8474513</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR5">
          <label>5.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Mandel</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Bond</surname>
                <given-names>JH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The effect of fecal occult-blood screening on the incidence of colorectal cancer</article-title>
            <source>N.Engl.J.Med.</source>
            <year>2000</year>
            <volume>343</volume>
            <fpage>1603</fpage>
            <lpage>1607</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJM200011303432203</pub-id>
            <pub-id pub-id-type="pmid">11096167</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR6">
          <label>6.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Atkin</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kralj-Hans</surname>
                <given-names>I</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>UK Flexible Sigmoidoscopy Trial Investigators: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial</article-title>
            <source>Lancet.</source>
            <year>2010</year>
            <volume>375</volume>
            <fpage>1624</fpage>
            <lpage>33</lpage>
            <pub-id pub-id-type="doi">10.1016/S0140-6736(10)60551-X</pub-id>
            <pub-id pub-id-type="pmid">20430429</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR7">
          <label>7.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bossuyt</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Irwig</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Craig J</article-title>
            <source>Glasziou P: Comparative accuracy: assessing new tests against existing diagnostic pathways BMJ.</source>
            <year>2006</year>
            <volume>332</volume>
            <fpage>1089</fpage>
            <lpage>1092</lpage>
          </mixed-citation>
        </ref>
        <ref id="CR8">
          <label>8.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Pepe</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Etzioni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Phases of biomarker development for early detection of cancer</article-title>
            <source>J Natl Cancer Inst.</source>
            <year>2001</year>
            <volume>93</volume>
            <fpage>1054</fpage>
            <lpage>1061</lpage>
            <pub-id pub-id-type="doi">10.1093/jnci/93.14.1054</pub-id>
            <pub-id pub-id-type="pmid">11459866</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR9">
          <label>9.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>St John</surname>
                <given-names>DJB</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Alexeyeff</surname>
                <given-names>MA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Evaluation of new occult blood tests for detection of colorectal neoplasia</article-title>
            <source>Gastroenterology</source>
            <year>1993</year>
            <volume>104</volume>
            <fpage>1661</fpage>
            <lpage>1668</lpage>
            <pub-id pub-id-type="pmid">8500724</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR10">
          <label>10.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Smith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Bampton</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia</article-title>
            <source>Cancer.</source>
            <year>2006</year>
            <volume>107</volume>
            <fpage>2152</fpage>
            <lpage>2159</lpage>
            <pub-id pub-id-type="doi">10.1002/cncr.22230</pub-id>
            <pub-id pub-id-type="pmid">16998938</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR11">
          <label>11.</label>
          <mixed-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Young</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <person-group person-group-type="editor">
              <name>
                <surname>Yamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kalloo</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>AN</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Owyang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Colorectal cancer screening</article-title>
            <source>Textbook of Gastroenterology</source>
            <year>2009</year>
            <edition>5</edition>
            <publisher-loc>Philadelphia</publisher-loc>
            <publisher-name>Lippincott Williams and Wilkins</publisher-name>
            <fpage>1598</fpage>
            <lpage>1610</lpage>
          </mixed-citation>
        </ref>
        <ref id="CR12">
          <label>12.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Jones</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Parmigiani</surname>
                <given-names>G</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Comparative lesion sequencing provides insights into tumor evolution</article-title>
            <source>Proc. Natl. Acad. Sci. U.S.A.</source>
            <year>2008</year>
            <volume>105</volume>
            <fpage>4283</fpage>
            <lpage>4288</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.0712345105</pub-id>
            <pub-id pub-id-type="pmid">18337506</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR13">
          <label>13.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Levin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>McFarland</surname>
                <given-names>B</given-names>
              </name>
              <collab>American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee</collab>
              <etal/>
            </person-group>
            <article-title>Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology</article-title>
            <source>Gastroenterology</source>
            <year>2008</year>
            <volume>134</volume>
            <fpage>1570</fpage>
            <lpage>95</lpage>
            <pub-id pub-id-type="doi">10.1053/j.gastro.2008.02.002</pub-id>
            <pub-id pub-id-type="pmid">18384785</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR14">
          <label>14.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Atkin</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Morson</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Cuzick</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Long-term risk of colorectal cancer after excision of rectosigmoid adenomas</article-title>
            <source>New Engl J Med</source>
            <year>1992</year>
            <volume>326</volume>
            <issue>10</issue>
            <fpage>658</fpage>
            <lpage>62</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJM199203053261002</pub-id>
            <pub-id pub-id-type="pmid">1736104</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR15">
          <label>15.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Winawer</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Zauber</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>O&#x2019;Brien</surname>
                <given-names>MJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup</article-title>
            <source>New Engl J Med</source>
            <year>1993</year>
            <volume>328</volume>
            <issue>13</issue>
            <fpage>901</fpage>
            <lpage>6</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJM199304013281301</pub-id>
            <pub-id pub-id-type="pmid">8446136</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR16">
          <label>16.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Strope</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Prostate cancer screening: current status and future perspectives</article-title>
            <source>Nat Rev Urol</source>
            <year>2010</year>
            <volume>7</volume>
            <issue>9</issue>
            <fpage>487</fpage>
            <lpage>93</lpage>
            <pub-id pub-id-type="doi">10.1038/nrurol.2010.120</pub-id>
            <pub-id pub-id-type="pmid">20818326</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR17">
          <label>17.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Hermsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Postma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baak</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability</article-title>
            <source>Gastroenterology</source>
            <year>2002</year>
            <volume>123</volume>
            <fpage>1109</fpage>
            <lpage>1119</lpage>
            <pub-id pub-id-type="doi">10.1053/gast.2002.36051</pub-id>
            <pub-id pub-id-type="pmid">12360473</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR18">
          <label>18.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Carvalho</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Postma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mongera</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression</article-title>
            <source>Gut</source>
            <year>2009</year>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <lpage>89</lpage>
            <pub-id pub-id-type="doi">10.1136/gut.2007.143065</pub-id>
            <pub-id pub-id-type="pmid">18829976</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR19">
          <label>19.</label>
          <mixed-citation publication-type="other">&#x2022;&#x2022;Bosch LJW, Carvalho B, Fijneman RJA, et al.: Molecular tests for colorectal cancer screening. Clin Colorectal Cancer 2011 Jan; in press. <italic>This is the best and most up-to-date review of the detail of molecular tests for colorectal cancer screening, having a more scientific focus. It also includes information on blood tests for screening.</italic></mixed-citation>
        </ref>
        <ref id="CR20">
          <label>20.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Osborn</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Ahlquist</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Stool screening for colorectal cancer: molecular approaches</article-title>
            <source>Gastroenterology</source>
            <year>2005</year>
            <volume>128</volume>
            <fpage>192</fpage>
            <lpage>206</lpage>
            <pub-id pub-id-type="doi">10.1053/j.gastro.2004.10.041</pub-id>
            <pub-id pub-id-type="pmid">15633136</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR21">
          <label>21.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Th&#xE9;ry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ostrowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Segura</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Membrane vesicles as conveyors of immune response</article-title>
            <source>Nat Rev Immunol.</source>
            <year>2009</year>
            <volume>9</volume>
            <fpage>581</fpage>
            <lpage>593</lpage>
            <pub-id pub-id-type="doi">10.1038/nri2567</pub-id>
            <pub-id pub-id-type="pmid">19498381</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR22">
          <label>22.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ahlquist</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Skoletsky</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Boynton</surname>
                <given-names>KA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel</article-title>
            <source>Gastroenterology</source>
            <year>2000</year>
            <volume>119</volume>
            <fpage>1219</fpage>
            <lpage>1227</lpage>
            <pub-id pub-id-type="doi">10.1053/gast.2000.19580</pub-id>
            <pub-id pub-id-type="pmid">11054379</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR23">
          <label>23.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Boynton</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Summerhayes</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Ahlquist</surname>
                <given-names>DA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>DNA integrity as a potential marker for stool-based detection of colorectal cancer</article-title>
            <source>Clin. Chem.</source>
            <year>2003</year>
            <volume>49</volume>
            <fpage>1058</fpage>
            <lpage>1065</lpage>
            <pub-id pub-id-type="doi">10.1373/49.7.1058</pub-id>
            <pub-id pub-id-type="pmid">12816901</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR24">
          <label>24.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Schuebel</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cope</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Comparing the DNA hypermethylome with gene mutations in human colorectal cancer</article-title>
            <source>PLoS. Genet.</source>
            <year>2007</year>
            <volume>3</volume>
            <fpage>1709</fpage>
            <lpage>1723</lpage>
            <pub-id pub-id-type="doi">10.1371/journal.pgen.0030157</pub-id>
            <pub-id pub-id-type="pmid">17892325</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR25">
          <label>25.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Calistri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rengucci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Molinari</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer</article-title>
            <source>Cell Oncol.</source>
            <year>2009</year>
            <volume>31</volume>
            <fpage>11</fpage>
            <lpage>17</lpage>
            <pub-id pub-id-type="pmid">19096146</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR26">
          <label>26.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Imperiale</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Ransohoff</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Itzkowitz</surname>
                <given-names>SH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2004</year>
            <volume>351</volume>
            <fpage>2704</fpage>
            <lpage>2714</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa033403</pub-id>
            <pub-id pub-id-type="pmid">15616205</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR27">
          <label>27.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ahlquist</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sargent</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Loprinzi</surname>
                <given-names>CL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Stool DNA and occult blood testing for screen detection of colorectal neoplasia</article-title>
            <source>Ann. Intern. Med.</source>
            <year>2008</year>
            <volume>149</volume>
            <fpage>441</fpage>
            <lpage>50</lpage>
            <pub-id pub-id-type="pmid">18838724</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR28">
          <label>28.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Itzkowitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brand</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jandorf</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A simplified, noninvasive stool DNA test for colorectal cancer detection</article-title>
            <source>Am. J. Gastroenterol.</source>
            <year>2008</year>
            <volume>103</volume>
            <fpage>2862</fpage>
            <lpage>2870</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1572-0241.2008.02088.x</pub-id>
            <pub-id pub-id-type="pmid">18759824</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR29">
          <label>29.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Chen</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Skoletsky</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene</article-title>
            <source>J. Natl. Cancer Inst.</source>
            <year>2005</year>
            <volume>97</volume>
            <fpage>1124</fpage>
            <lpage>1132</lpage>
            <pub-id pub-id-type="doi">10.1093/jnci/dji204</pub-id>
            <pub-id pub-id-type="pmid">16077070</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR30">
          <label>30.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Tagore</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Yucaitis</surname>
                <given-names>JA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia</article-title>
            <source>Clin. Colorectal Cancer</source>
            <year>2003</year>
            <volume>3</volume>
            <fpage>47</fpage>
            <lpage>53</lpage>
            <pub-id pub-id-type="doi">10.3816/CCC.2003.n.011</pub-id>
            <pub-id pub-id-type="pmid">12777192</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR31">
          <label>31.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Slaby</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Svoboda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Michalek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vyzula</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>MicroRNAs in colorectal cancer: translation of molecular biology into clinical application</article-title>
            <source>Molecular Cancer</source>
            <year>2009</year>
            <volume>8</volume>
            <fpage>102</fpage>
            <pub-id pub-id-type="doi">10.1186/1476-4598-8-102</pub-id>
            <pub-id pub-id-type="pmid">19912656</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR32">
          <label>32.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>LaPointe</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Dunne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>GS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Map of Differential Transcript Expression in the Normal Human Large Intestine</article-title>
            <source>Physiological Genomics</source>
            <year>2008</year>
            <volume>33</volume>
            <fpage>50</fpage>
            <lpage>64</lpage>
            <pub-id pub-id-type="doi">10.1152/physiolgenomics.00185.2006</pub-id>
            <pub-id pub-id-type="pmid">18056783</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR33">
          <label>33.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Kanaoka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening</article-title>
            <source>Gastroenterology</source>
            <year>2004</year>
            <volume>127</volume>
            <fpage>422</fpage>
            <lpage>427</lpage>
            <pub-id pub-id-type="doi">10.1053/j.gastro.2004.05.022</pub-id>
            <pub-id pub-id-type="pmid">15300574</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR34">
          <label>34.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Leung</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>To</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Man</surname>
                <given-names>EP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps</article-title>
            <source>Am. J. Gastroenterol.</source>
            <year>2007</year>
            <volume>102</volume>
            <fpage>1070</fpage>
            <lpage>1076</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1572-0241.2007.01108.x</pub-id>
            <pub-id pub-id-type="pmid">17378912</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR35">
          <label>35.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Koga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yasunaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moriya</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis</article-title>
            <source>Cancer Sci.</source>
            <year>2008</year>
            <volume>99</volume>
            <fpage>1977</fpage>
            <lpage>1983</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1349-7006.2008.00987.x</pub-id>
            <pub-id pub-id-type="pmid">19016757</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR36">
          <label>36.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Takai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanaoka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening</article-title>
            <source>Cancer Epidemiol. Biomarkers Prev.</source>
            <year>2009</year>
            <volume>18</volume>
            <fpage>1888</fpage>
            <lpage>1893</lpage>
            <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-08-0937</pub-id>
            <pub-id pub-id-type="pmid">19505922</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR37">
          <label>37.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yajima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Expression profiling of fecal colonocytes for RNA-based screening of colorectal cancer</article-title>
            <source>Int. J. Oncol.</source>
            <year>2007</year>
            <volume>31</volume>
            <fpage>1029</fpage>
            <lpage>1037</lpage>
            <pub-id pub-id-type="pmid">17912428</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR38">
          <label>38.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Mulder</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Leerdam</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Vuuren</surname>
                <given-names>AJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer</article-title>
            <source>Eur. J. Gastroenterol. Hepatol.</source>
            <year>2007</year>
            <volume>19</volume>
            <fpage>878</fpage>
            <lpage>882</lpage>
            <pub-id pub-id-type="doi">10.1097/MEG.0b013e3282cfa49c</pub-id>
            <pub-id pub-id-type="pmid">17873612</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR39">
          <label>39.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Shastri</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Povse</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schroder</surname>
                <given-names>O</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Comparison of a novel fecal marker&#x2013;fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study</article-title>
            <source>Clin. Lab</source>
            <year>2008</year>
            <volume>54</volume>
            <fpage>389</fpage>
            <lpage>390</lpage>
            <pub-id pub-id-type="pmid">19097497</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR40">
          <label>40.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Haug</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hundt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study</article-title>
            <source>Br. J. Cancer</source>
            <year>2008</year>
            <volume>99</volume>
            <fpage>133135</fpage>
          </mixed-citation>
        </ref>
        <ref id="CR41">
          <label>41.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Karl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wild</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tacke</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers</article-title>
            <source>Clin. Gastroenterol. Hepatol.</source>
            <year>2008</year>
            <volume>6</volume>
            <fpage>1122</fpage>
            <lpage>1128</lpage>
            <pub-id pub-id-type="doi">10.1016/j.cgh.2008.04.021</pub-id>
            <pub-id pub-id-type="pmid">18928937</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR42">
          <label>42.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Xing</surname>
                <given-names>PX</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A new approach to fecal occult blood testing based on the detection of haptoglobin</article-title>
            <source>Cancer</source>
            <year>1996</year>
            <volume>78</volume>
            <fpage>48</fpage>
            <lpage>56</lpage>
            <pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19960701)78:1&lt;48::AID-CNCR9&gt;3.0.CO;2-D</pub-id>
            <pub-id pub-id-type="pmid">8646726</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR43">
          <label>43.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Sieg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thoms</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Luthgens</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces</article-title>
            <source>Int. J. Colorectal Dis.</source>
            <year>1999</year>
            <volume>14</volume>
            <fpage>267</fpage>
            <lpage>271</lpage>
            <pub-id pub-id-type="doi">10.1007/s003840050226</pub-id>
            <pub-id pub-id-type="pmid">10663892</pub-id>
          </mixed-citation>
        </ref>
        <ref id="CR44">
          <label>44.</label>
          <mixed-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Roon</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Karamountzos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Purkayastha</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy</article-title>
            <source>Am. J. Gastroenterol.</source>
            <year>2007</year>
            <volume>102</volume>
            <fpage>803</fpage>
            <lpage>813</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1572-0241.2007.01126.x</pub-id>
            <pub-id pub-id-type="pmid">17324124</pub-id>
          </mixed-citation>
        </ref>
      </ref-list>
    </ref-list>
  </back>
</article>
